Resiliva 80 mg Capsule

Generic Name: Lenvatinib
Brand Name: Resiliva
Strength: 80 mg
Form: Oral Capsules
Pack Size: Commonly 30 capsules per bottle (varies)
Manufacturer: Everest Pharmaceuticals
Distributed by: NP Molecule

Indications:

Resiliva (Lenvatinib) is indicated for the treatment of:

• Differentiated thyroid cancer (DTC) that is refractory to radioactive iodine therapy

• Advanced renal cell carcinoma (RCC) in combination with pembrolizumab or everolimus

• Hepatocellular carcinoma (HCC) in patients who are not candidates for surgery or transarterial chemoembolization

• Endometrial carcinoma (in combination with pembrolizumab), in certain advanced or recurrent settings

Pharmacology:

Lenvatinib is a multi-kinase inhibitor targeting:

• VEGFR1, VEGFR2, VEGFR3

• FGFR1–4, PDGFRα

• RET and KIT

It works by inhibiting pathways involved in tumor angiogenesis, proliferation, and survival, effectively slowing tumor growth and spread.

Dosage & Administration:

• The typical starting dose for different indications ranges from 8 mg to 24 mg daily, depending on cancer type and combination therapy.

• Resiliva 80 mg provides flexibility for weight-based dosing or higher daily requirements.

• Taken once daily, with or without food.

• Dose adjustments are based on tolerance and side effects.

Drug Interactions:

• Caution with strong CYP3A4 inducers or inhibitors.

• May interact with drugs that affect blood pressure or prolong QT interval.

Contraindications:

• Hypersensitivity to Lenvatinib or any capsule component.

• Use with caution in patients with severe hepatic or renal impairment.

Side Effects:

• Common: Hypertension, fatigue, diarrhea, decreased appetite, weight loss, proteinuria.

• Serious: Cardiac dysfunction, liver toxicity, bleeding, gastrointestinal perforation, QT prolongation.

Pregnancy & Lactation:

• Contraindicated in pregnancy due to fetal harm risk.

• Avoid breastfeeding during and for at least 1 week after the last dose.

Precautions & Warnings:

• Regular monitoring of blood pressure, liver enzymes, kidney function, and thyroid levels is required.

• Caution in patients with a history of bleeding or cardiovascular disease.

Overdose Effects:

• May lead to severe hypertension and increased risk of serious adverse effects.

• Supportive and symptomatic treatment is essential.

Therapeutic Class:

• Tyrosine Kinase Inhibitor (TKI)

• Anti-angiogenic Therapy

Storage Conditions:

• Store below 30°C in a dry place.

• Protect from moisture and light.

• Keep out of reach of children.